期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

西格列汀对新诊断2型糖尿病患者高敏C反应蛋白的影响 被引量：1

下载PDF
导出
摘要 目的观察西列汀对新诊断2型糖尿病(T2DM)患者血清高敏C反应蛋白(hs-CRP)的影响。方法将56例新诊断的T2DM患者被随机分成观察组和对照组,遵循个性化饮食及运动方案;观察组在生活方式干预基础上服用西格列汀100 mg/d。随访12周,观察2组空腹血糖(FBG)、餐后2 h血糖(2hPG)、糖化血红蛋白(HbA1c)及hs-CRP水平。结果 T2DM患者hs-CRP水平显著高于健康人群(P<0.05);12周后观察组hs-CRP、FBG、2hPG及HbA1c较对照组均明显下降(P均<0.05)。结论西格列汀可显著降低T2DM患者血糖及血清hs-CRP水平。
作者 吴心池 方铭 胥娟 唐伟
机构地区 东南大学附属江阴医院
出处 《现代中西医结合杂志》 CAS 2014年第20期2248-2250,共3页 Modern Journal of Integrated Traditional Chinese and Western Medicine
关键词 2型糖尿病 西格列汀 C反应蛋白
分类号 R587.1 [医药卫生—内分泌]
  • 相关文献

参考文献10

  • 1Yang W,Lu J,Weng J,et al.Prevalence of diabetes among men and women in china[J].N Engl J Med,2010,362(12):1090-1101.
  • 2Wellen KE,Hotamisligil GS.Inflammation,stress,and oxidative stress[J].J Clin Invest,2005,115:1111-1119.
  • 3王先令,陆菊明,潘长玉.不同糖耐量水平者血清C反应蛋白水平及阿卡波糖干预的影响[J].中华内分泌代谢杂志,2003,19(4):254-256. 被引量：43
  • 4Dehghan A,Kardys I,de Maat M,et al.Genetic variation,C-reactive protein levels,and incidence of diabetes[J].Diabetes,2007,56(3):872-878.
  • 5Freeman DJ,Nerre J,Caslake MJ,et al.C-reactive protein is an independent predictor of risk for the development of diabetes in the west Scotland coronary prevention[J].Diabetes,2002,51(19):1596-1598.
  • 6Nauck MA,Meininger G,Sheng D,et al.Efficacy and safety of the dipeptidyl peptidase-4 inhibitor,sitagliptin,compared with the sulfonylurea,glipizide,in patients with type 2 diabetes inadequately controlled on metformin alone:A randomized,double-blind,non-inferiority trial[J].Diabetes Obes Metab,2007,9(2):194-205.
  • 7Hattori S.Sitagliptin reduces albuminuria in patents with type 2 diabetes[J].Endocr J,2011,58(1):69-73.
  • 8Bo S,Ciccone G,Baldi C,et al.Effectiveness of a lifestyle intervention on metabolic syndrome.A Randomized Controlled Trial[J].J Gen Intern Med,2007,22(12):1695-1703.
  • 9Fadini GP,Boscaro E,Albicro M,et al.The oral dipeptidyl peptidase-4 inhibitor sitagliptin increases circulating endothelial progenitor cells in patients with type 2 diabetes mellitus[J].Diabetes Care,2010,33(7):1607-1609.
  • 10Ishibashi Y,Matsui T,Takeuchi M,et al.Glucagon-like peptide-1(GLP-1)inhibits advanced glycation end product(AGE)-induced up-regulation of VCAM-1 mRNA levels in endothelial cells by suppressing AGE receptor(RAGE)expression[J].Biochem Biophys Res Commun,2010,391(3):1405-1408.

二级参考文献8

  • 1Temelkova-Kurktschiev T, Henkel E, Schaper F, et al. Prevalence and atherosclerosis risk in different types of non-diabetic hyperglycemia. Is mild hyperglycemia and underestimated evil? Exp Clin Endocrinol Diabetes, 2000,108:93-99.
  • 2Pickup JC, Crook MA. Is type Ⅱ diabetes mellitus a disease of the innate immune system? Diabetologia, 1998,41:1241-1248.
  • 3Pickup JC, Mattock MB, Chuseney GD, et al. NIDDM as a disease of the innate immune system: association of acute-phase reactants and interleukin-6 with metabolic syndrome X. Diabetologia, 1997,40:1286-1292.
  • 4McMillan DE. Increased levels of acute-phase serum proteins in diabetes. Metabolism, 1989,38:1042-1046.
  • 5Pradhan AD, Manson JE, Rifai N, et al. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA, 2001,286:327-334.
  • 6Ebeling P, Tepppo AM, Koistinen HA, et al. Troglitazone reduces hyperglycaemia and selectively acute-phase serum proteins with type Ⅱ diabetes. Diabetologia, 1999,42:1433-1438.
  • 7Yuan M, Konstantopoulos N, Lee J, et al. Reversal of obesity- and diet-induced insulin resistance with salicylates or targeted disruption of Ikkbeta. Science, 2001,293:1673-1677.
  • 8董吉祥,石永兵,韩惠琴,沈华英,谢炜,谢莹,刘志达,张学光.2型糖尿病患者血清白细胞介素-6、肿瘤坏死因子-α水平与T细胞亚群变化的研究[J].中华内分泌代谢杂志,1999,15(6):370-371. 被引量：21

共引文献42

同被引文献13

引证文献1

二级引证文献14

现代中西医结合杂志
2014年 第20期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部